EFEMP1 and cancer: The finding that EFEMP1 is, overall, tumor-suppressive is consistent with the favorable effect of EFEMP1 expression in the overall prognosis of patients with GBM [16], breast [21], liver [22], lung [23], and nasopharynx [23], and the finding that EFEMP1 is downregulated and/or silenced via methylation of the EFEMP1 promoter in cancer tissues of breast [21], colon [24], liver [22], lung [25, 26], nasopharynx [23], and prostate [27, 28], and recently in gastric cancer [29].